PTC Therapeutics, Inc. Gross Margin

Gross Margin of PTCT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending September 29, 2021 was 84.92% (a 2.6% increase compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -2.38%
  • Annual Gross Margin for 2020 was 85.34% (a -1.95% decrease from previous year)
  • Annual Gross Margin for 2019 was 87.04% (a 0.54% increase from previous year)
  • Annual Gross Margin for 2018 was 86.57% (a -3.52% decrease from previous year)
  • Twelve month Gross Margin ending September 29, 2021 was 84.38% (a -0.86% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by -5.95% year-over-year
Trailing Gross Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
84.38% 85.11% 87.12% 89.72%
Visit stockrow.com/PTCT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of PTC Therapeutics, Inc.

Most recent Gross Marginof PTCT including historical data for past 10 years.

Interactive Chart of Gross Margin of PTC Therapeutics, Inc.

PTC Therapeutics, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 84.92% 82.77% 82.72%
2020 86.99% 87.93% 92.95% 94.02% 85.34%
2019 96.33% 95.79% 96.25% 95.57% 87.04%
2018 95.64% 93.86% 96.26% 94.57% 86.57%
2017 97.18% 96.22% 98.42% 99.85% 89.73%
2016 100.0% 100.0% 100.0% 100.0% 100.0%
2015 100.0% 100.0% 100.0% 100.0% 100.0%
2014 100.0% 100.0% 100.0% 100.0% 100.0%
2013 100.0% 100.0% 100.0% 100.0% 100.0%
2012 100.0% 100.0% 100.0% 100.0% 100.0%
2011 100.0%

Business Profile of PTC Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.